Nautilus Biotechnology (NASDAQ:NAUT) Issues Quarterly Earnings Results

Nautilus Biotechnology (NASDAQ:NAUT) posted its quarterly earnings results on Tuesday. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.04, Zacks reports. During the same quarter in the previous year, the business earned ($0.13) EPS.

Nautilus Biotechnology Price Performance

NASDAQ NAUT traded down $0.12 during trading on Wednesday, hitting $2.65. 43,413 shares of the company’s stock traded hands, compared to its average volume of 74,739. The stock has a fifty day moving average of $2.75 and a two-hundred day moving average of $2.62. Nautilus Biotechnology has a 12-month low of $2.19 and a 12-month high of $3.45. The firm has a market cap of $332.34 million, a P/E ratio of -4.73 and a beta of 1.22.

Insider Activity

In other news, VP Mary E. Godwin sold 47,031 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $2.87, for a total transaction of $134,978.97. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 40.50% of the company’s stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.